LTTS2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member LTTS2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentRevenue01Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentRevenue02Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentRevenue03Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentRevenue04Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentRevenue05Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentRevenue01Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentRevenue02Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentRevenue03Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentRevenue04Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentRevenue05Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentResults01Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentResults02Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentResults03Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentResults04Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentResults05Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentResults01Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentResults02Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentResults03Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentResults04Member LTTS2020-01-012020-03-31in-bse-fin:FourReportableSegmentResults05Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentAssets01Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentAssets02Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentAssets03Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentAssets04Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentAssets05Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentLiabilities01Member LTTS2020-03-31in-bse-fin:OneReportableSegmentLiabilities01Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentLiabilities02Member LTTS2020-03-31in-bse-fin:OneReportableSegmentLiabilities02Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentLiabilities03Member LTTS2020-03-31in-bse-fin:OneReportableSegmentLiabilities03Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentLiabilities04Member LTTS2020-03-31in-bse-fin:OneReportableSegmentLiabilities04Member LTTS2020-01-012020-03-31in-bse-fin:OneReportableSegmentLiabilities05Member LTTS2020-03-31in-bse-fin:OneReportableSegmentLiabilities05Member LTTS2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LTTS2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member LTTS2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LTTS2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member LTTS2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LTTS2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member LTTS2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member LTTS2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LTTS 2019-04-01 2020-03-31 2020-05-04 INR Millions Yearly Multi segment 2020-01-01 2020-03-31 Audited Standalone 13241000000.00 633000000.00 13874000000.00 0.00 0.00 0.00 7544000000.00 94000000.00 408000000.00 3318000000.00 11364000000.00 2510000000.00 0.00 2510000000.00 530000000.00 73000000.00 603000000.00 0.00 1907000000.00 0.00 0.00 0.00 0.00 1907000000.00 -1988000000.00 -81000000.00 0.00 0.00 209000000.00 2 18.26 18.06 0.00 0.00 18.26 18.06 Explanatory notes to the statement of audited standalone financial results for the quarter and year ended March 31, 2020 n n1. The interim standalone financial statements for the quarter and year ended March 31, 2020 and the audited standalone financial statements for the year ended March 31, 2020 have been taken on record by the Board of Directors at its meeting held on May 15, 2020. The statutory auditors, Sharp & Tannan have expressed an unqualified audit opinion. The information for the year ended March 31, 2020 presented above is extracted from the audited standalone financial statements and the information for quarter ended March 31, 2020 are extracted from the interim standalone financial statements. These standalone financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter. n n2. During the quarter ended March 31, 2020, the Company has allotted 167,523 equity shares of Rs. 2 each fully paid-up on exercise of stock options by employees, in accordance with the Company's stock option scheme. n n3. The Company has adopted Ind AS 116 – Leases, with effect from April 1, 2019 by using modified retrospective approach and accordingly comparatives for the year ended March 31, 2019 have not been adjusted retrospectively. Consequently, the Company has not restated the comparative figures and cumulative effect of initially applying this Standard have been recognised as adjustment to opening balance of retained earnings as on April 1, 2019. n n4. The Board of Directors have recommended a final dividend of Rs. 13.5 per equity share (face value Rs. 2) for the year ended March 31,2020 and the final dividend is payable subject to the approval of the shareholders at the eighth annual general meeting. n n5. The figures for the quarter ended March 31, 2020 and March 31, 2019 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarters ended December 31, 2019 and December 31, 2018 respectively. n n6. Estimation uncertainty relating to COVID-19: nThe Company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on current estimates, the Company expects to fully recover the carrying amount of trade receivables including unbilled receivables, intangible assets and investments. The Company has considered internal and certain external sources of information including reliable credit reports, economic forecasts and industry reports up to the date of approval of the financial statements in determining the impact on various elements of its financial statements. Management of the Company has also reviewed goodwill nand is of the opinion that no impairment is required at present. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial statements. n n7. Figures for earlier periods have been regrouped, wherever necessary. Multi segment 2019-04-01 2020-03-31 Audited Standalone 51813000000.00 2123000000.00 53936000000.00 0.00 0.00 0.00 29659000000.00 351000000.00 1534000000.00 11842000000.00 43386000000.00 10550000000.00 0.00 10550000000.00 2083000000.00 567000000.00 2650000000.00 0.00 7900000000.00 0.00 0.00 0.00 0.00 7900000000.00 -2603000000.00 5297000000.00 0.00 0.00 209000000.00 2 0.00 75.82 74.99 0.00 0.00 75.82 74.99 Other expenses 3318000000.00 Other expenses 11842000000.00 Industrial Products 2664000000.00 Medical Devices 1470000000.00 Plant Engineering 2320000000.00 Telecom & Hitech 2338000000.00 Transportation 4449000000.00 Industrial Products 10717000000.00 Medical Devices 5109000000.00 Plant Engineering 9101000000.00 Telecom & Hitech 9872000000.00 Transportation 17014000000.00 13241000000.00 51813000000.00 0.00 0.00 13241000000.00 51813000000.00 Industrial Products 618000000.00 Medical Devices 412000000.00 Plant Engineering 526000000.00 Telecom & Hitech 340000000.00 Transportation 604000000.00 Industrial Products 2695000000.00 Medical Devices 1397000000.00 Plant Engineering 2315000000.00 Telecom & Hitech 1649000000.00 Transportation 3064000000.00 2500000000.00 11120000000.00 94000000.00 351000000.00 -104000000.00 Notes for segment information naSegments have been identified in accordance with Indian Accounting Standards ( Ind AS ) 108 on Operating Segments, considering the risk/return profiles of the business, their organisational structure and internal reporting systems. nb Property, plant and equipment used and liabilities contracted for performing the Company's business have not been identified to any of the above reported segments as the property, plant and equipment and services are used interchangeably among segments. 219000000.00 2510000000.00 10550000000.00 Industrial Products 0.00 Medical Devices 0.00 Plant Engineering 0.00 Telecom & Hitech 0.00 Transportation 0.00 0.00 0.00 0.00 Industrial Products 0.00 Medical Devices 0.00 Plant Engineering 0.00 Telecom & Hitech 0.00 Transportation 0.00 0.00 0.00 0.00